References No. of fractions No. of patients/no. of total patients Fractional dose (isocenter, Gy) Median followup (months) Local control Dose calculation algorithm Kopek et al. [17 ] 3 62/88 15.0 44.0 93.1% P
Koto et al. [22 ] 20/31 15.0 32.0 75.0% Bath
Hoyer et al. [24 ] 40/40 15.0 29.0 92.5% NS
Bral et al. [35 ] 23/40 18.0 16.0 91.3% NSS, BrainLa
Ricardi et al. [26 ] 62/62 18.8 28.0 93.6% C
Guckenberger et al. [37 ] 32/124 19.2 14.0 100.0% C
Ng et al. [30 ] 12/20 20.0 21.0 83.3% NSS, BrainLa
Andratschke et al. [31 ] 92/92 20.8* 21.0 89.1% NS
Nyman et al. [18 ] 45/45 21.0 43.0 80.0% Bath
Vahdat et al. [19 ] 20/20 21.3* 43.0 95.0% NSS, Cyberknif
Crabtree et al. [33 ] 76/76 21.8 19.0 93.4% NSS, Triolog
Baumann et al. [20 ] 57/57 22.0 35.0 93.0% P
Timmerman et al. [21 ] 59/59 22.5 34.4 98.2% NS
Turzer et al. [38 ] 31/36 22.9 13.8 100.0% C
Fakiris et al. [16 ] 34/70 25.0 50.2 97.1% NS
van der Voort van Zyp et al. [36 ] 59/70 25.8 15.0 96.6% NSS, Cyberknif
Matsuo et al. [23 ] 4 101/101 12 31.4 86.1% PB Baba et al. [28 ] 85/124 12 26.0 87.1% NSS Stephans et al. [32 ] 5 56/86 10.2 19.8 96.4% NSS, BrainLa
Takeda et al. [29 ] 63/63 12.5 24.0 95.6% SC Lagerwaard et al. [25 ] >100‡ /— 15.0 29.0 95.7% NSS, BrainLa
Onimaru et al. [34 ] 8 to 10 17/45 6.0 18.0 70.6% PB & S
Onishi et al. [39 ] 35/35 7.3 13.0 94.3% NS
Xia et al. [27 ] 43/43 10.0 27.0 96.0% NSS, Gamma knife